乳腺癌治疗后心力衰竭或心肌病风险预测模型
本研究在Kaiser Permanente Southern California纵向队列中,纳入2008至2020年新诊断浸润性早期乳腺癌的18-79岁女性,开发并验证预测10年心力衰竭或心肌病(HF/CM)风险的多变量弹性网Cox模型;验证队列低危组10年HF/CM风险1.7%(95%CI 1.1%-2.4%),高危组19.4%(95%CI 17.3%-21.5%),10年时间依赖AUC为0.79。
要点
- 模型基于诊断时年龄、种族、社会经济地位、治疗、分期、肥胖及心血管病史等变量。
- 验证队列低危组10年HF/CM风险1.7%,高危组19.4%。
- 模型10年时间依赖AUC为0.79,区分度良好且校准良好。
核心结论
- 该模型可基于乳腺癌诊断时选定的治疗和临床变量,前瞻性识别10年内HF/CM风险的早期乳腺癌女性。
- 模型可用于指导这些女性的风险导向心脏管理。
研究设计与样本
- 纵向队列研究,数据来自Kaiser Permanente Southern California整合医疗系统。
- 纳入2008至2020年新诊断浸润性局部或区域乳腺癌的18-79岁女性,中位随访5.2年。
- 使用多变量弹性网Cox比例风险模型预测10年HF/CM风险。
主要发现
- 验证队列中低危组10年HF/CM风险为1.7%(95%CI 1.1%-2.4%),与推导队列估计一致。
- 验证队列中高危组10年HF/CM风险为19.4%(95%CI 17.3%-21.5%),与推导队列估计一致。
- 验证队列10年时间依赖AUC为0.79,模型区分能力良好。
- 模型在低、中、高三个风险亚组中校准良好且预测准确性高。
临床怎么用
- 对早期乳腺癌女性,可在诊断时利用模型变量评估10年HF/CM风险。
- 根据低、中、高危分层,可 informing 风险导向的心脏管理策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Women receiving breast cancer (BC) treatment are at risk for heart failure or cardiomyopathy (HF/CM). No standard method exists to identify women at risk who might benefit from preventive cardiac strategies and surveillance during and after treatment. OBJECTIVE: To develop and validate a model predicting the 10-year risk of developing HF/CM in women receiving systemic treatment for invasive early-stage BC to inform cardiac risk management. DESIGN, SETTING, AND PARTICIPANTS: This longitudinal cohort study of patients cared for in Kaiser Permanente Southern California, a vertically integrated health care system. The goal of the study was to predict the 10-year HF/CM risk using multivariable elastic-net Cox proportional hazards models. Women aged 18 to 79 years with newly diagnosed invasive local or regional BC from 2008 to 2020, with a median follow-up of 5.2 years, were included. The cohort was randomly split into derivation (60%) and validation (40%) cohorts. Data were analyzed from April 2024 to May 2025. EXPOSURES: HF/CM risk predictors included age at BC diagnosis, race and ethnicity, area-level socioeconomic status, local and systemic BC treatments, cancer stage, obesity, and history of hypertension, diabetes, hyperlipidemia, smoking, and other CV conditions. MAIN OUTCOME AND MEASURES: Incident HF/CM events. Women were categorized into low-, moderate-, and high-risk groups based on the tertiles of the risk score in the derivation cohort. RESULTS: Of 26 044 women included in the total cohort, the median (IQR) age was 61 (52-68) years. The risk model had good calibration and high accuracy in predicting HF/CM risk in the 3 subgroups, with HF/CM risk in the validation cohort matching the estimates from the derivation for identifying women at low risk (1.7%; 95% CI, 1.1%-2.4%) and high risk (19.4%; 95% CI. 17.3%-21.5%) of HF/CM at 10 years. The model's discrimination ability was good, based on the time-dependent area under the curve of 0.79 at 10 years in the validation cohort. CONCLUSIONS AND RELEVANCE: This risk prediction model among women with early-stage BC was able to prospectively identify those at risk of HF/CM over a 10-year period based on the selected BC treatment and clinical variables available at BC diagnosis. The model can be used to inform risk-guided cardiac management for these women.
引用
- Barac A, Chou J, Shara N, et al. Risk Prediction Model for Development of Heart Failure or Cardiomyopathy After Breast Cancer Treatment. JAMA Oncol. 2025. PMID: 41129144. doi:10.1001/jamaoncol.2025.4178
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。